Set to be the first pre-rev­enue biotech to list in Hong Kong, As­cle­tis lays out pri­or­i­ties in IPO ap­pli­ca­tion

As­cle­tis is get­ting the ball rolling on the first pre-rev­enue biotech IPO in Hong Kong.

Hangzhou-based As­cle­tis, whose in-house he­pati­tis C drug is on the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.